← Oncology Approval Tracker

FDA DECISION ·

Noxafil PowderMix

posaconazole delayed-release oral suspension · Merck

FDA approvalNew formulationInvasive fungal infection prophylaxis
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Prophylaxis against invasive Aspergillus and Candida infections for high-risk children age 2 and older weighing 40 kg or less, including recipients of hematopoietic stem cell transplantation with GVHD and children with hematologic malignancy and prolonged chemotherapy-related neutropenia.

LAMPGEN ANALYSIS

Why it matters

The delayed-release suspension supplies a weight-defined pediatric formulation for patients at high risk of invasive fungal disease.

What research teams should watch

Check age and weight, record the specific posaconazole formulation and plan drug-interaction and administration checks.

PRIMARY RECORDS

Sources